Creative Biolabs Advances Antibody Non-GMP Production and Quality Control

Guidance from the World Health Organization highlights the importance of stringent quality control in antibody production for therapeutic use, a niche that Creative Biolabs is filling with its non-GMP antibody production services. The company's focus on flexible, high-quality research-grade antibodies offers a solution to the industry's demand for specialized QC services, which are currently scarce. Research, including studies found on PubMed, underscores the significance of glycosylation in antibody efficacy and safety, further emphasizing the need for precise QC measures.

Creative Biolabs has developed a custom antibody production and QC service pipeline to accelerate the development of therapeutic monoclonal antibody candidates. This includes managing both upstream and downstream processes, with tailored approaches for each project. Their OmicsAb™ High-throughput Antibody Production service enables the rapid production of diverse antibody candidates, ensuring high purity and specific characteristics through an innovative QC system.

The company also specializes in the production and QC of multispecific antibodies, handling complex engineering tasks to create molecules that enhance drug targeting and minimize off-target effects. Additionally, their scFv-Fc fusion platform offers a combination of agility and precision, supporting clients with end-to-end QC and technical support for their research needs.

Beyond its antibody services, Creative Biolabs is committed to fostering the next generation of scientists through its 2025 Scholarship Program, which supports students in biology-related fields. This initiative reflects the company's dedication to advancing scientific research and innovation.